<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156169</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-01-2358-AH-CTIL</org_study_id>
    <nct_id>NCT00156169</nct_id>
  </id_info>
  <brief_title>The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.</brief_title>
  <official_title>The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of fibrates on high density lipoprotein (HDL)-cholesterol levels is suggested to
      be mediated by its binding to peroxisome proliferator-activated receptor-g (PPARg). Upon
      ligand binding, PPARg heterodimerizes with the 9-cis retinoic acid receptor (RXR), and the
      heterodimer regulates gene expression. We assessed the hypothesis that a dual treatment with
      fibrate plus 9-cis b-carotene-rich powder of the alga Dunaliella bardawil, as a source of
      9-cis retinoic acid, would improve the drug's effect on HDL-cholesterol levels.

      patients with plasma HDL-cholesterol levels below 40 mg/dl and triglyceride (TG) levels above
      200 mg/dl after fibrate treatment (for at least 6 weeks). are given four capsules of
      Dunaliella, providing 60 mg b-carotene/day. The all-trans to 9-cis b-carotene ratio in the
      capsules is about 1:1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Low HDL Cholesterol</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dunaliella</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-70 years

          -  Fibrate treatment (for at least 6 weeks)

          -  HDL-Cholesterol lower than 40mg/dl.

          -  Triglyceride over 150mg/dl.

        Exclusion Criteria:

          -  High CPK.

          -  Elevated liver functions.

          -  Active CHD.

          -  Smokers.

          -  Diabetes patients treated with Insulin or Avandia. HbA1C great than 8.5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayelet Harari, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alitretinoin</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

